Drugs.com - Monthly Update June 2026

This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers.Lumvoa (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness.Utebzi (tebipenem pivoxil): The first oral carbapenem approved in the U.S., providing a new option for treating complicated urinary tract infections, demonstrating efficacy comparable to intravenous options.Tregzi (Orca-T or allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq): A precision-engineered cell therapy for use in donor stem cell transplantation, to help rebuild the blood and immune system, and to improve chronic graft-versus-host disease (GVHD)-free survival, in adults with blood cancers (hematological malignancies).Chapters:(00:21) - Intro (00:41) - Lumvoa (01:42) - Utebzi (02:42) - Tregzi (03:21) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app